Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
Author
Summary, in English
Dyskinesias are a major complication of long-term l-3,4-dihydroxyphenylalanine (L-DOPA) treatment in Parkinson's disease, and are believed to result from the intermittent and pulsatile supply of L-DOPA. Daily injections of L-DOPA can prime similar abnormal involuntary movements of the limb, orolingual and axial muscles in rats rendered parkinsonian by destruction of the nigrostriatal dopamine (DA) neurons. In this study we used 33 rats with severe nigrostriatal dopamine depletion and showed that in vivo gene transfer of the DA-synthetic enzymes tyrosine hydroxylase (TH) and GTP cyclohydrolase 1 (GCH1) using recombinant adeno-associated virus vectors can provide a constant source of DOPA production locally in the striatum, at a level that is effective in reducing L-DOPA-induced dyskinesias by >85%, and reverse lesion-induced motor impairments. Furthermore, the abnormal expression of DeltaFosB, prodynorphin and preproenkephalin mRNA within the striatal projection neurons normally seen in dyskinetic animals was completely reversed by TH-GCH1 gene transfer. These findings form a strong basis for replacing, or supplementing, conventional systemic L-DOPA therapy by continuous intrastriatal DOPA using in vivo gene transfer in the treatment of patients with advanced Parkinson's disease.
Department/s
Publishing year
2005
Language
English
Pages
559-569
Publication/Series
Brain
Volume
128
Issue
3
Links
Document type
Journal article
Publisher
Oxford University Press
Topic
- Neurology
Keywords
- dyskinesia
- gene therapy
- GTP cyclohydrolase 1
- Parkinson's disease
- tyrosine hydroxylase
Status
Published
Research group
- Brain Repair and Imaging in Neural Systems (BRAINS)
- Neuronano Research Center (NRC)
- Basal Ganglia Pathophysiology
- Neurobiology
ISBN/ISSN/Other
- ISSN: 1460-2156